Drug Search Results
More Filters [+]

AD4-ENVC150

Alternative Names: ad4-envc150, ad4envc150, ad4 envc150
Latest Update: 2024-03-18
Latest Update Note: Clinical Trial Update

Product Description

A live replication-competent Adenovirus type-4 vector encoding an HIV clade C Env protein (gp150 1086.C) (Sourced from: https://clinicaltrials.gov/ct2/show/NCT02771730)

Mechanisms of Action: Vaccine

Novel Mechanism: No

Modality: Vaccine

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Emergent
Company Location: GAITHERSBURG MD 20879
Company CEO: Robert G. Kramer
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for AD4-ENVC150

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: HIV Infections|Protein Deficiency|Eye Infections|Vaginal Discharge|Adenovirus Infections, Human

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

14-I-0011

P1

Completed

Vaginal Discharge|Eye Infections|HIV Infections|Protein Deficiency|Adenovirus Infections, Human

2019-04-08

Recent News Events

Date

Type

Title